(-0.07%) 5 474.75 points
(-0.11%) 38 776 points
(-0.03%) 19 915 points
(0.20%) $80.49
(1.15%) $2.82
(0.22%) $2 334.20
(-0.14%) $29.35
(-0.22%) $968.80
(0.00%) $0.932
(-0.17%) $10.64
(0.06%) $0.788
(-1.87%) $86.79
Live Chart Being Loaded With Signals
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders...
Stats | |
---|---|
Šios dienos apimtis | 1.24M |
Vidutinė apimtis | 566 901 |
Rinkos kapitalizacija | 915.89M |
EPS | $-1.950 ( Q3 | 2022-11-08 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-6.63 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.932 (2.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-02 | Chiswell David | Sell | 56 278 | Common Stock |
2023-03-02 | Chiswell David | Sell | 8 000 | Stock Option (Right to Buy) |
2023-03-02 | Chiswell David | Sell | 8 000 | Stock Option (Right to Buy) |
2023-03-02 | Chiswell David | Sell | 8 000 | Stock Option (Right to Buy) |
2023-03-02 | Chiswell David | Sell | 5 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-50.94 |
Last 100 transactions |
Buy: 1 059 000 | Sell: 2 762 067 |
Tūris Koreliacija
Albireo Pharma Inc Koreliacija
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Albireo Pharma Inc Koreliacija - Valiuta/Žaliavos
Albireo Pharma Inc Finansinės ataskaitos
Annual | 2021 |
Pajamos: | $40.58M |
Bruto pelnas: | $39.22M (96.66 %) |
EPS: | $-1.770 |
FY | 2021 |
Pajamos: | $40.58M |
Bruto pelnas: | $39.22M (96.66 %) |
EPS: | $-1.770 |
FY | 2020 |
Pajamos: | $8.31M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-6.73 |
FY | 2019 |
Pajamos: | $9.64M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-5.04 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Albireo Pharma Inc
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.